Diagnosis of Pulmonary and Extra Pulmonary Tuberculosis: How Best is CBNAAT when Compared to Conventional Methods of TB Detection?
DOI:
https://doi.org/10.17140/PRRMOJ-4-137Keywords:
Cartridge-based nucleic acid amplification test (CBNAAT), Tuberculosis, Sputum smearAbstract
Background: Globally, India is a home for more than 25% of global Tuberculosis (TB) burden. The sensitivity of smear microscopy and its inability to detect drug resistance limits its impact on TB control. We compared the cartridge-based nucleic acid amplification test (CBNAAT) results for diagnosis of pulmonary and extrapulmonary tuberculosis with the conventional meth-ods like sputum smear and solid culture examination.
Methods: A descriptive study was conducted at Government General and Chest Hosptial, Hyderabad, India during 2014 to 2016. The study population included all the pulmonary and ex-trapulmonary presumptive TB cases who were subjected for further investigations.
Results: Of the two hundred samples received, 110 (55%) were sputum samples and 90 (45%) were extrapulmonary samples. For pulmonary samples, the sensitivity and specificity for CB-NAAT samples were 79.2% and 89.5% respectively; while that for sputum smear were 41.5% and 98.2% respectively. For extrapulmonary samples, the sensitivity and specificity for CB-NAAT samples were 85.7% and 93.5% respectively; while that for sputum smear were 60.7% and 100% respectively.
Conclusion: CBNAAT is one of the rapid diagnostic tests available in the country and it should be routinely used under the public and private health sector effectively to detect a tuberculosis case.
References
World Health Organisation. Global Tuberculosis Report 2015. Geneva; 2015. Web site. http://www.who.int/tb/publications/ global_report/en/. Accessed August 17, 2017.
Urdea M, Penny LA, Olmsted SS, et al. Requirements for high impact diagnostics in the developing world. Nature. 2006; 444: 73-79. doi: 10.1038/nature05448
Xpert MTB/RIF implementation manual IMPLEMENTA-TION MANUAL [Internet]. 2014. Web site. www.who.int/tb. Accessed August 17, 2017.
Panayotis I, Papaventsis D, Karabela S, et al. Cepheid GeneX-pert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with substan-tial clinical indications of tuberculosis and smear-negative mi-croscopy results. J Clin Microbiol. 2011; 49(8): 3068-3070. doi: 10.1128/JCM.00718-11
Armand S, Vanhuls P, Delcroix G, Courcol R, Lemaître N. Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tu-berculosis in respiratory and nonrespiratory specimens. J Clin Microbiol. 2011; 49(5): 1772-1776. doi: 10.1128/JCM.02157-10
Raizada N, Sachdeva KS, Sreenivas A, et al. Catching the missing million: Experiences in enhancing TB & amp; DR-TB detection by providing upfront xpert MTB/RIF testing for peo-ple living with HIV in India. PLoS One. 2015; 10(2): e0116721. doi: 10.1371/journal.pone.0116721
Sachdeva KS, Raizada N, Sreenivas A, et al. Use of Xpert MTB/RIF in decentralized public health settings and its effect on pulmonary TB and DR-TB case finding in India. PLoS One. 2015; 10(5): e0126065. doi: 10.1371/journal.pone.0126065
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pulmonary Research and Respiratory Medicine (PRRM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
